Uroplasty, Inc. (NASDAQ:UPI)’s director, Kevin H Roche, recently declared a new position in its stock with 10,000 shares common stock. He acquired them for prices ranging from $2.90 per share to $3.02 per share.
Following the last reported transaction, Mr. Roche directly owns about 10,000 securities at the surgical and medical instruments and apparatus company.
Moreover, on the past few days, Robert Kill, Uroplasty, Inc. (NASDAQ:UPI)’s President and CEO, purchased 500,000 shares at about $3 per share.
In addition, several hedge funds are betting on this company. For instance, Nathan Fischel’s Dafna Capital Management, owns 289,332 shares, and Joseph Edelman’s Perceptive Advisors, holds 517,791 shares, up 65% on first quarter. Other large shareholders, such as Sophrosyne Capital,Manatuck Hill Partners and Orbimed Advisors, have been investing and betting on Uroplasty, Inc.(NASDAQ:UPI) for the past quarter.
Kevin H Roche also leads Virtual Radiologic Corp (VRAD) company but does not report insider activity in it.